Item 9 Labs Corp. (INLB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Item 9 Labs Corp. (INLB) trades at $0.00 with AI Score 45/100 (Grade C). Item 9 Labs Corp. is a vertically integrated cannabis operator and dispensary franchisor in the United States. Market cap: $70,181, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for INLB: INLB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INLB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INLB: the 1 perspectives are evenly split.
How is this calculated? →Item 9 Labs Corp. (INLB) Healthcare & Pipeline Overview
Item 9 Labs Corp. operates as a vertically integrated cannabis company, producing and distributing cannabis products through its dispensaries and franchised Unity Rd locations. Focused on the Arizona market, the company navigates the evolving regulatory landscape of the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for INLB?
Item 9 Labs Corp. presents a unique investment opportunity within the cannabis sector due to its vertically integrated business model and dispensary franchising strategy. The company's focus on the Arizona market, combined with its Unity Rd franchise network, positions it for growth as the cannabis industry matures. However, investors may want to evaluate the risks associated with operating in a highly regulated and competitive market. With a negative P/E ratio and a negative profit margin of -143.1%, the company's profitability is a concern. Key growth catalysts include expansion of the dispensary network and increased brand recognition. The company's gross margin of 33.6% indicates potential for improved profitability with scale. The company's beta of 0.15 suggests low volatility relative to the market.
Based on FMP financials and quantitative analysis
INLB Key Highlights
- Vertically integrated operations provide control over the entire cannabis value chain, from cultivation to retail.
- Franchise model through Unity Rd offers a scalable approach to expanding dispensary network.
- Focus on the Arizona market allows for targeted marketing and distribution strategies.
- Gross margin of 33.6% indicates potential for profitability improvements.
- Negative profit margin of -143.1% highlights the need for improved cost management and revenue growth.
Who Are INLB's Competitors?
INLB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INLB's Key Strengths?
- Vertically integrated operations
- Franchise model for expansion
- Established presence in Arizona
- Diverse product offerings
What Are INLB's Weaknesses?
- Negative profitability
- Limited geographic diversification
- Reliance on a single state market (Arizona)
- Small market capitalization
What Could Drive INLB Stock Higher?
- Expansion of dispensary network through new openings and franchise growth.
- Increasing legalization of cannabis in additional states, creating new market opportunities.
- Product innovation and development of new cannabis-derived products.
- Potential strategic partnerships or acquisitions to expand market reach.
- Brand building and marketing efforts to increase brand awareness and customer loyalty.
What Are the Key Risks for INLB?
- Financial-distress signal — its Altman Z-Score of -2.03 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-42.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory uncertainty and changes in cannabis laws.
- Intense competition from other cannabis companies.
- Fluctuations in cannabis prices and supply.
- Negative profitability and the need for improved cost management.
- Limited access to capital and financing challenges.
What Are the Growth Opportunities for INLB?
- Expansion of Dispensary Network: Item 9 Labs Corp. can expand its revenue by opening new dispensaries in Arizona and other states where cannabis is legal. The legal cannabis market is projected to reach $50 billion by 2026, providing a significant growth opportunity for companies with established retail networks. The company's Unity Rd franchise model offers a capital-efficient way to expand its footprint. This expansion could be executed over the next 3-5 years.
- Product Innovation and Diversification: Item 9 Labs Corp. can drive growth by introducing new cannabis products and expanding its product offerings. The company can focus on developing innovative products that cater to specific consumer needs and preferences. This could include new strains of cannabis, edibles, topicals, and other cannabis-derived products. The timeline for this growth opportunity is immediate and ongoing.
- Strategic Partnerships and Acquisitions: Item 9 Labs Corp. can accelerate its growth by forming strategic partnerships with other companies in the cannabis industry. This could include partnerships with cultivators, processors, distributors, and retailers. The company can also pursue acquisitions of complementary businesses to expand its product offerings and market reach. The timeline for this growth opportunity is within the next 2-3 years.
- Brand Building and Marketing: Item 9 Labs Corp. can invest in building its brand and marketing its products to increase brand awareness and customer loyalty. The company can use a variety of marketing channels, including social media, digital advertising, and traditional advertising. The company can also sponsor events and participate in industry trade shows to promote its brand. The timeline for this growth opportunity is immediate and ongoing.
- Franchise Expansion: Item 9 Labs Corp. can significantly grow its revenue by expanding its Unity Rd franchise network across multiple states. The company can target states with favorable cannabis regulations and a strong demand for cannabis products. This expansion can be achieved through targeted marketing campaigns and by offering attractive franchise terms to potential franchisees. The timeline for this growth opportunity is within the next 3-5 years.
What Opportunities Does INLB Have?
- Expansion into new states
- Product innovation and diversification
- Strategic partnerships and acquisitions
- Increasing legalization of cannabis
What Threats Does INLB Face?
- Regulatory uncertainty
- Intense competition
- Fluctuations in cannabis prices
- Changing consumer preferences
What Are INLB's Competitive Advantages?
- Vertically integrated operations provide cost advantages and quality control.
- Unity Rd franchise network offers a scalable expansion model.
- Established presence in the Arizona cannabis market.
What Does INLB Do?
Item 9 Labs Corp., headquartered in Phoenix, Arizona, is a vertically integrated cannabis operator and dispensary franchisor. The company cultivates, processes, and retails cannabis and cannabis-related products. Its operations span various product categories, including flower, concentrates, distillates, and hardware. Item 9 Labs distributes its products through its own licensed dispensaries and through franchised locations operating under the Unity Rd brand. The company focuses primarily on the Arizona market, catering to both medical and adult-use cannabis consumers. Its business model integrates cultivation, manufacturing, distribution, and retail sales, allowing for greater control over product quality and supply chain efficiency. Item 9 Labs also seeks to expand its footprint through franchising, offering entrepreneurs the opportunity to operate cannabis dispensaries under a recognized brand. The company's vertically integrated approach aims to capture a larger share of the cannabis value chain, from seed to sale. The company's strategy involves expanding its dispensary network and product offerings to meet the growing demand for cannabis products in Arizona and beyond.
What Products and Services Does INLB Offer?
- Cultivates cannabis plants.
- Processes cannabis into various products like flower, concentrates, and distillates.
- Manufactures cannabis-related hardware.
- Operates licensed cannabis dispensaries in Arizona.
- Sells medical and adult-use cannabis products.
- Franchises cannabis dispensaries under the Unity Rd brand.
How Does INLB Make Money?
- Vertically integrated operations from cultivation to retail sales.
- Generates revenue through direct sales at company-owned dispensaries.
- Earns franchise fees and royalties from Unity Rd franchisees.
What Industry Does INLB Operate In?
Item 9 Labs Corp. operates within the rapidly evolving cannabis industry, which is characterized by increasing legalization and growing consumer demand. The market is highly competitive, with numerous companies vying for market share. The company's vertically integrated model and franchise strategy differentiate it from some competitors, but it also faces challenges from larger, well-capitalized players. The industry is subject to significant regulatory uncertainty, which can impact operations and profitability. The company's focus on the Arizona market provides a degree of geographic concentration, but also exposes it to state-specific regulatory risks.
Who Are INLB's Key Customers?
- Medical cannabis patients in Arizona.
- Adult-use cannabis consumers in Arizona.
- Entrepreneurs seeking to operate cannabis dispensaries through the Unity Rd franchise program.
F-Score 3/9Financial Health
Item 9 Labs Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.03 places it in the distress zone, a signal of elevated financial risk.
INLB Valuation & Market Position
With a 70K market cap, Item 9 Labs Corp. sits in the micro-cap segment of the market. Relative to its peer group, INLB's quantitative score of 45/100 is below the peer average of 66/100.
ROE -42%Key Financial Metrics
Return on equity for Item 9 Labs Corp. stands at -42.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -28.1%, showing how much profit it generates from its asset base. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Item 9 Labs Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Phoenix, US. The company is led by CEO Jeffrey I. Rassas. INLB has traded publicly since 2012.
INLB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Vertically integrated operations
- Franchise model for expansion
- Established presence in Arizona
- Diverse product offerings
Bear Case
- Negative profitability
- Limited geographic diversification
- Reliance on a single state market (Arizona)
- Small market capitalization
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
INLB Latest News
No recent news available for INLB.
INLB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INLB.
Price Targets
Wall Street price target analysis for INLB.
INLB MoonshotScore
What does this score mean?
The MoonshotScore rates INLB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jeffrey I. Rassas
CEO
Jeffrey I. Rassas serves as the CEO of Item 9 Labs Corp. His background includes experience in managing and scaling businesses, though specific details on his prior roles and education are not available. He has been instrumental in guiding Item 9 Labs' growth strategy, focusing on vertical integration and franchise expansion. His leadership is focused on navigating the complex regulatory landscape of the cannabis industry and driving revenue growth.
Track Record: Under Jeffrey I. Rassas's leadership, Item 9 Labs Corp. has expanded its dispensary network and franchise operations. He has overseen the development of new cannabis products and the implementation of strategic partnerships. His focus has been on building a sustainable and scalable business model in the rapidly evolving cannabis market. However, the company's path to profitability remains a key challenge.
INLB OTC Market Information
OTC Other, also known as the Grey Market, represents the lowest tier of the OTC market. Companies in this tier often do not meet minimum financial standards and may not provide regular financial disclosures. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ. These companies may be defunct, experiencing financial distress, or unwilling to adhere to higher reporting standards. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in an OTC Other company.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any legal or regulatory issues.
- Understand the risks associated with the OTC Other tier.
- Consult with a qualified financial advisor.
- Company's operational status (active vs. defunct)
- Existence of a physical headquarters and operational facilities
- Presence of a management team and employees
- Any available news or press releases about the company
- Information from third-party sources (if available)
Item 9 Labs Corp. Healthcare Stock: Key Questions Answered
What does Item 9 Labs Corp. do?
Item 9 Labs Corp. operates as a vertically integrated cannabis company, handling everything from cultivation and processing to retail sales and franchise operations. The company produces a range of cannabis products, including flower, concentrates, and distillates, which are sold through its own dispensaries and franchised Unity Rd locations. The company primarily focuses on the Arizona market, serving both medical and adult-use cannabis consumers. Its vertically integrated approach allows for greater control over product quality and supply chain efficiency, while its franchise model provides a scalable avenue for expansion.
What do analysts say about INLB stock?
As of March 16, 2026, there is no readily available analyst coverage or consensus on Item 9 Labs Corp. (INLB) stock, likely due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before considering an investment in INLB. Key valuation metrics, such as price-to-earnings ratio, are currently not meaningful due to the company's negative profitability. Growth considerations include the company's ability to expand its dispensary network and improve its financial performance.
What are the main risks for INLB?
Item 9 Labs Corp. faces several risks inherent to the cannabis industry, including regulatory uncertainty, intense competition, and fluctuations in cannabis prices. The company's reliance on the Arizona market exposes it to state-specific regulatory risks. Its negative profitability and small market capitalization also present financial challenges. As an OTC-listed company, INLB is subject to less stringent regulatory oversight and may have limited liquidity, increasing the risk for investors. Investors should carefully consider these risks before investing in INLB.
What are the key factors to evaluate for INLB?
Item 9 Labs Corp. (INLB) holds an AI score of 45/100 (low). Not financial advice.
How frequently does INLB data refresh on this page?
INLB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven INLB's recent stock price performance?
Item 9 Labs Corp. (INLB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Vertically integrated operations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INLB overvalued or undervalued right now?
Valuing Item 9 Labs Corp. (INLB) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying INLB?
Before investing in Item 9 Labs Corp. (INLB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC listing and disclosure status.
- Analyst coverage is not available for this stock.